Literature DB >> 6316841

Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis.

J M Decazes, J D Ernst, M A Sande.   

Abstract

Ceftriaxone was highly active in eliminating Escherichia coli from the cerebrospinal fluid of rabbits infected with experimental meningitis. However, concentrations equal to or greater than 10 times the minimal bactericidal concentration had to be achieved to ensure optimal efficacy (rate of kill, 1.5 log10 CFU/ml per h). In contrast to other beta-lactams studied in this model, ceftriaxone concentrations in cerebrospinal fluid progressively increased, whereas serum steady state was obtained by constant infusion. The percent penetration was 2.1% after 1 h of therapy, in contrast to 8.9% after 7 h (P less than 0.001). In vitro time-kill curves done in cerebrospinal fluid or broth more closely predicted the drug concentrations required for a maximum cidal effect in vivo than that predicted by determinations of minimal inhibitory or bactericidal concentrations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6316841      PMCID: PMC185356          DOI: 10.1128/AAC.24.4.463

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  [The antibiotic therapy laboratory in purulent meningitis].

Authors:  Y A Chabbert
Journal:  Sem Hop       Date:  1967-01-20

Review 2.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

3.  Treatment of purulent meningitis with a new cephalosporin-Rocephin (Ro 13-9904). Clinical, bacteriological and pharmacological observations in 24 cases.

Authors:  M Cadoz; F Denis; H Félix; I Diop Mar
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

4.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

5.  Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.

Authors:  W M Scheld; M A Sande
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

6.  Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics.

Authors:  K Stoeckel; P J McNamara; R Brandt; H Plozza-Nottebrock; W H Ziegler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

7.  In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis.

Authors:  G H McCracken; J D Nelson; L Grimm
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

9.  Efficacy of ceftriaxone in serious bacterial infections.

Authors:  J S Epstein; S M Hasselquist; G L Simon
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

View more
  19 in total

1.  Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors:  F Fitoussi; C Doit; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

2.  Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.

Authors:  R Garraffo; H B Drugeon; P Dellamonica; E Bernard; P Lapalus
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.

Authors:  W Kern; S L Kennedy; M Sachdeva; E R Sande; D Gunderson; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

4.  Evaluation of pefloxacin in experimental Escherichia coli meningitis.

Authors:  A M Shibl; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

Review 5.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

6.  Susceptibility of Haemophilus influenzae type b to ampicillin-sulbactam.

Authors:  P H Azimi; M G Dunphy
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.

Authors:  I Lutsar; A Ahmed; I R Friedland; M Trujillo; L Wubbel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 8.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

9.  Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.

Authors:  B Pangon; V Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.